Simpson Thacher Leads Banks In Samsung Biologics' $2B IPO
Simpson Thacher & Bartlett LLP said Wednesday it represented six investment banks underwriting a $2 billion initial public offering for Samsung Biologics, the drug manufacturing arm of the South Korean conglomerate...To view the full article, register now.
Already a subscriber? Click here to view full article